✉ Email this page to a colleague
« Back to Dashboard
SCY-635 is an investigational drug.
There have been 14 clinical trials for SCY-635. The most recent clinical trial was a Phase 3 trial, which was initiated on November 15th 2017.
The most common disease conditions in clinical trials are Candidiasis, Candidiasis, Vulvovaginal, and Candidiasis, Invasive. The leading clinical trial sponsors are Scynexis, Inc., Clinical Network Services (CNS) Pty Ltd, and ethica Clinical Research Inc.
There are one hundred and sixty-eight US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for SCY-635
|A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole||Scynexis, Inc.||Phase 3|
|Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects||Clinical Network Services (CNS) Pty Ltd||Phase 1|
|Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects||Scynexis, Inc.||Phase 1|
Top disease conditions for SCY-635
Top clinical trial sponsors for SCY-635
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|SCY-635||⤷ Try a Trial||1',4'-thio nucleosides for the treatment of HCV||IDENIX PHARMACEUTICALS LLC (Cambridge, MA)||⤷ Try a Trial|
|SCY-635||⤷ Try a Trial||Benzimidazole derivatives||Enanta Pharmaceuticals, Inc. (Watertown, MA)||⤷ Try a Trial|
|SCY-635||⤷ Try a Trial||Anti-viral compounds||AbbVie Inc. (North Chicago, IL)||⤷ Try a Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|SCY-635||European Patent Office||EP3004130||2033-06-05||⤷ Try a Trial|
|SCY-635||World Intellectual Property Organization (WIPO)||WO2014197578||2033-06-05||⤷ Try a Trial|
|SCY-635||Australia||AU2010217797||2029-02-27||⤷ Try a Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|